In 2002 the NHI (National Institutes of Health) started a massive study on EDTA chelation therapy, the study was called TACT and it proved that this treatment did reduce the risk of heart attacks, strokes and other heart problems. The trial also found out that Chelation Therapy seemed to have a greater effect on those with diabetes. As a result another trial has been arranged and is due for completion in the year 2021.

Note: The type of EDTA used in the TACT trials is the same as Cardio Renew, that is disodium EDTA and NOT calcium disodium EDTA which is wrongly taken by some and marketed by some companies for artery blockage. You can monitor any progress with the new TACT 2 trials on the official website here https://clinicaltrials.gov/ct2/show/study/NCT02733185